title: American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.
abstract: The 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, held in Atlanta, included topics covering disclosures of new data in the field of pharmacokinetics and drug interactions. This conference report highlights selected presentations on pharmacokinetic studies of several investigational drugs, including evatanepag (Pfizer Inc), AEG-33773 (Aegera Therapeutics Inc), JNJ-16269110 (Johnson & Johnson Pharmaceutical Research & Development LLC), PF-3716539 (ViiV Healthcare), MK-0736 (Merck & Co Inc), a combination of Ginkgo biloba and cilostazol (Renexin SK Chemicals Co Ltd), PP-101 (Pacific Pharmaceuticals Co Ltd), ACT-178882 (Acetlion Ltd/Merck & Co Inc) and edoxaban (Daiichi Sankyo Co Ltd).
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. claire.veryard@thomsonreuters.com
authors.forename: Claire
authors.initials: C
authors.lastname: Veryard
mesh_terms: D002986:Clinical Trials as Topic; D015195:Drug Design; D004347:Drug Interactions; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*
chemical_list: D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations